Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (101-110 of 266) with videos related to

Pageof 27
Sort By:
Frontiers in Oncology|August 17, 2023
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological featuresAlbert Font, Montserrat Domenech, Jose Luis Ramirez, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2014
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinomaXavier García Del Muro, Enrique Gallardo, Iciar García Carbonero, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2018
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancerOliver W Hakenberg, Jose Luis Perez-Gracia, Daniel Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2017
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANAStéphane Oudard, Karim Fizazi, Lisa Sengeløv, et al.
European Urology|September 15, 2014
Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in EuropeKarim Fizazi, Per-Anders Abrahamsson, Goran Ahlgren, et al.
The Lancet. Oncology|July 21, 2009
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialMartin E Gore, Cezary Szczylik, Camillo Porta, et al.
Pharmacogenetics and Genomics|April 22, 2017
Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinomaMaría Apellániz-Ruiz, Meta H Diekstra, Juan M Roldán, et al.
Genome Biology|October 3, 2022
H3K18 lactylation marks tissue-specific active enhancersEva Galle, Chee-Wai Wong, Adhideb Ghosh, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2016
Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi TechniqueCarlos Camps, Joan Albanell, Antonio Antón, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 4, 2024
Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in SpainJavier Puente, Alvaro Pinto, Maria José Mendez-Vidal, et al.
Pageof 27

Showing results (101-110 of 266) with videos related to

Sort By:
Pageof 27
Frontiers in Oncology|August 17, 2023
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological featuresAlbert Font, Montserrat Domenech, Jose Luis Ramirez, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2014
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinomaXavier García Del Muro, Enrique Gallardo, Iciar García Carbonero, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2018
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancerOliver W Hakenberg, Jose Luis Perez-Gracia, Daniel Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2017
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANAStéphane Oudard, Karim Fizazi, Lisa Sengeløv, et al.
European Urology|September 15, 2014
Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in EuropeKarim Fizazi, Per-Anders Abrahamsson, Goran Ahlgren, et al.
The Lancet. Oncology|July 21, 2009
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialMartin E Gore, Cezary Szczylik, Camillo Porta, et al.
Pharmacogenetics and Genomics|April 22, 2017
Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinomaMaría Apellániz-Ruiz, Meta H Diekstra, Juan M Roldán, et al.
Genome Biology|October 3, 2022
H3K18 lactylation marks tissue-specific active enhancersEva Galle, Chee-Wai Wong, Adhideb Ghosh, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2016
Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi TechniqueCarlos Camps, Joan Albanell, Antonio Antón, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 4, 2024
Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in SpainJavier Puente, Alvaro Pinto, Maria José Mendez-Vidal, et al.
Pageof 27